投机快报

kelvin234

回复 660# SUNNY仔


    sunny..你賺還蠻多了啦.
我決定不看mpel了:@

ps:我常常都在車壇潛水的,看見你和89兄開罵戰 很激烈下哦...

pcmont

sunny你不到三十水
已经做拥多少百千了
还是新币的
真是好有本事

miku

恭喜 roberto  !

顺便恭喜 sunny, miku 炒股赚大钱置业.......入伙请吃是几时?

也问侯下...仙家大 ...
m.i.k.e 发表于 13-1-2010 12:52 PM

有人恭喜我？谢谢。setapak kl， 会来吗？

miku

车坛在哪里？我最喜欢看人吵架。

jochen

XRTX -  15.25  了。。。。。


可惜我 15.15 卖了。。。。

有人买吗？

还会上的。。。。。。 ...
jochen 发表于 12-1-2010 11:06 PM

xrtx  - 这3天 上的好猛！！！！！
16。45

痛死了。。。


16.45
+1.20(7.87%)

jochen

XRTX -  15.25  了。。。。。


可惜我 15.15 卖了。。。。

有人买吗？

还会上的。。。。。。 ...
jochen 发表于 12-1-2010 11:06 PM

xrtx  - 这3天 上的好猛！！！！！
16。45

痛死了。。。


16.45
+1.20(7.87%)

夜心情

看开点...果然amd也上了...,你就等他回跌在买进吧

kelvin234

我刚刚看见一个帖,不关股票事的,只是觉得文章蛮有趣,所以paste过来这里,看看relax下.
年轻漂亮MM想嫁有钱人，如何嫁有钱人
一个年轻漂亮的美国女孩在美国一家大型网上论坛金融版上发表了这样一个问题帖：我怎样才能嫁给有钱人？
“我下面要说的都是心里话。本人25岁，非常漂亮，是那种让人惊艳的漂亮，谈吐文雅，有品位，想嫁给年薪 50万美元的人。你也许会说我贪心，但在纽约年薪100万才算是中产，本人的要求其实不高。
　　这个版上有没有年薪超过 50万的人？你们都结婚了吗？我想请教各位一个问题——怎样才能嫁给你们这样的有钱人？我约会过的人中，最有钱的年薪25万，这似乎是我的上限。要住进纽约中心公园以西的高尚住宅区，年薪25万远远不够。我是来诚心诚意请教的。有几个具体的问题：一、有钱的单身汉一般都在哪里消磨时光？　(请列出酒吧、饭店、健身房的名字和详细地址。)二、我应该把目标定在哪个年龄段？三、为什么有些富豪的妻子看起来相貌平平？我见过有些女孩，长相如同白开水，毫无吸引人的地方，但她们却能嫁入豪门。而单身酒吧里那些迷死人的美女却运气不佳。四、你们怎么决定谁能做妻子，谁只能做女朋友？　(我现在的目标是结婚。)”—— 波尔斯女士

下面是一个华尔街金融家的回帖：
“亲爱的波尔斯：我怀着极大的兴趣看完了贵帖，相信不少女士也有跟你类似的疑问。让我以一个投资专家的身份，对你的处境做一分析。我年薪超过50万，符合你的择偶标准，所以请相信我并不是在浪费大家的时间。
　　从生意人的角度来看，跟你结婚是个糟糕的经营决策，道理再明白不过，请听我解释。抛开细枝末节，你所说的其实是一笔简单的“财”“貌”交易：甲方提供迷人的外表，乙万出钱，公平交易，童叟无欺。但是，这里有个致命的问题，你的美貌会消逝，但我的钱却不会无缘无故减少。事实上，我的收入很可能会逐年涕增．而你不可能一年比一年漂亮。
　　因此，从经济学的角度讲，我是增值资产，你是贬值资产，不但贬值，而且是加速贬值!你现在25，在未来的五年里，你仍可以保持窈窕的身段，俏丽的容貌，虽然每年略有退步。但美貌消逝的速度会越来越快，如果它是你仅有的资产，十年以后你的价值甚忧。
　　用华尔街术语说，每笔交易都有一个仓位，跟你交往属于“交易仓位”(tradinglposition)，一旦价值下跌就要立即抛售，而不宜长期持有 ——也就是你想要的婚姻。听起来很残忍，但对一件会加速贬值的物资，明智的选择是租赁，而不是购入。年薪能超过50万的人，当然都不是傻瓜，因此我们只会跟你交往，但不会跟你结婚。所以我劝你不要苦苦寻找嫁给有钱人的秘方。顺便说一句，你倒可以想办法把自己变成年薪50万的人，这比碰到一个有钱的傻瓜的胜算要大。　　希望我的回帖能对你有帮助。如果你对“租赁”感兴趣，请跟我联系。”——罗波．坎贝尔（JP摩根银行多种产业投资顾问）

葉芬

現在等著 ANX。。。。。

最好給我勇勇的過 0.50 ！

葉芬

还是金钱比较实在,对吗?

忘了恭喜你最近赚番天,风骚cari 国际股票区.


...
m.i.k.e 发表于 13-1-2010 08:38 PM

  一天不耍我都不行。。。




幾時要去新加坡？

jochen

xrtx  - 这3天 上的好猛！！！！！
16。45

痛死了。。。


16.45
+1.20(7.87%)
jochen 发表于 14-1-2010 01:29 AM

17.04
+1.79(11.74%)

SUNNY仔

回复  SUNNY仔


    sunny..你賺還蠻多了啦.
我決定不看mpel了

ps:我常常都在車壇潛水的,看見你 ...
kelvin234 发表于 13-1-2010 10:57 PM

    我也很久没蒲车坛啦....一时看到那些帖会晕..被人跟貼貼开个帖来谈;出路口没人让又开个贴来谈;撞死一只老鼠也开个贴来谈 然后呢..时常说他跑了多快多快的...闲....那个89..哎.,可能八十后都是酱的嘛..??

m.i.k.e

新年快樂，師父   遲了些些。


呵呵 好在我叫的夠大聲，師父才聽得到。
近排去了那裏呢？ ...

P/s: 你的FRE放了嗎？
葉芬 发表于 13-1-2010 01:32 PM

FRE 还捉在手上.

第一次升到$1.6左右时,人在渡假.
第二次升到$1.6左右时,人在住院.

都错过了.....

roberto

Economic Calendar Data - 1/14/10


Initial Jobless Claims - Last Week - 8:30am EST - expected  430,000

Retails Sales - December 2009 - 8:30am EST - expected  0.70%

roberto

Earnings Calendar - Companies Reporting Earnings - 1/14/10


Origin Agritech SEED 1/14 8am   -.06EPS

Intel INTC 1/14 4pm   .31EPS

roberto

Top Stocks to Watch - January 14, 2009


MDRNA, Inc. (MRNA)
Converted Organics Inc (COIN)
Antigenics Inc. (AGEN)
Baidu, Inc. (BIDU)
UAL Corporation (UAUA)

roberto

Stocks to Watch - 1/14/10 - Stock Market Investing Ideas

Antigenics Inc. (AGEN)- Shares of Antigenics Inc. soared Wednesday on no news. This is astock worth watching on Thursday. Resistance is located at $1.41 whichis the 200 day moving average.

Pacific Ethanol, Inc. (PEIX)- Pacific Ethanol, Inc cooled off Wednesday but is still a stock thatis high on my radar. On Tuesday, PEIX closed over $2.40 which wasbullish. I plan to buy the stock when it breaks above $2.44 which wasWednesday's high of day.

Cyclacel Pharmaceuticals, Inc. (CYCC)- I continue to watch Cyclacel Pharmaceuticals, Inc which exploded lastweek on positive drug data. Resistance is located at $3.20 & $3.60.

Cell Therapeutics, Inc. (CTIC)- CTIC stock was up about 17% Wednesday afternoon as we are just monthsaway from an FDA decision on Pixantrone. A close above $1.30 would bevery bullish.

葉芬

FRE 还捉在手上.

第一次升到$1.6左右时,人在渡假.
第二次升到$1.6左右时,人在住院.

都错过了 ...
m.i.k.e 发表于 14-1-2010 09:08 AM

住院？ 希望不是大事。
真心祝福你早日安康。。。。。




P/s: 看來你的FRE 第三次應該是一飛沖天。
下次有事情給個電話我，我可以幫忙你賣。。

葉芬

Monday,  18 Jan 2010  is a US Holiday, Martin Luther King, Jr. Day.  

All US Markets will be closed.

葉芬

SNSS

1.27 -0.03 (-2.34%)
Pre-market: 1.38 +0.11 (8.70%)
Jan 14, 8:03AM EST  


Jan 14, 2010 07:30 ET
Sunesis Announces Publication of Nonclinical Voreloxin Data in Leukemias

Studies Demonstrate Voreloxin Acts Synergistically With Cytarabine and Induces Bone Marrow Aplasia

SOUTH SAN FRANCISCO, CA--(Marketwire - January 14, 2010) - Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the publication of new nonclinical studies with the Company's lead drug candidate, voreloxin, in the journal Cancer Chemotherapy and Pharmacology. The results demonstrate voreloxin's potent cytotoxic activity in human acute leukemia cell lines and in an in vivo model when used alone, and enhanced or synergistic activity when used in combination with cytarabine. Sunesis is currently completing Phase 2 studies of voreloxin as a single-agent or in combination with cytarabine in acute myeloid leukemia (AML) and expects to begin Phase 3 testing in AML later in 2010.

"These data contribute to our growing understanding of voreloxin's nonclinical profile, and, in keeping with our philosophy of clinical development informed by translational research, are directly relevant to our clinical program," said Judith A. Fox, Ph.D., Vice President of Product and Preclinical Development at Sunesis. "We studied voreloxin alone and in combination with cytarabine in leukemia cell lines, as well as in a mouse model of bone marrow ablation. The additive and synergistic effects of the combination in vitro, coupled with the supra-additive effects of the drugs in vivo, translate directly to our ongoing Phase 2 AML program. Importantly, the effects of voreloxin and the combination regimen on bone marrow were fully reversible, mirroring the treatment paradigm for AML."

Voreloxin, alone and in combination with cytarabine, was evaluated in 3 human acute leukemia cell lines: HL-60 (acute promyelocytic leukemia), MV4-11 (AML with a FLT3 mutation) and CCRF-CEM (acute lymphoblastic leukemia). Voreloxin was active in all the leukemia cell lines, including the AML cell line, which is relatively resistant to cytarabine in vitro. Using a combination index (CI) analysis, voreloxin with cytarabine demonstrated synergistic cytotoxic activity HL-60 and MV4-11 cells, and additive activity in CCRF-CEM cells.

In a series of elegant in vivo studies, a murine model of bone marrow ablation was used to evaluate the activity of voreloxin and cytarabine alone and in combination. Bone marrow cellularity, peripheral white blood cell and platelet counts were monitored to assess the impact of and recovery from the study treatments. Voreloxin alone or in combination with cytarabine caused reversible bone marrow ablation accompanied by profound reductions in peripheral white blood cells that were reversible within one week, consistent with the therapeutic goals of AML treatment. The activity of voreloxin at maximum tolerated dose (MTD) was superior to cytarabine at MTD. In addition, the combination demonstrated supra-additive activity in vivo, with a substantially enhanced, but fully reversible, reduction in bone marrow cellularity as compared to each agent alone.

The Cancer Chemotherapy and Pharmacology article and full, published data set are available online at www.springerlink.com/content/n7577n7281832171/.

About Voreloxin

Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that nearly 13,000 new cases of AML will be diagnosed and approximately 9,000 deaths from AML will occur in the U.S. in 2009. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.